A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Neutropenia|Breast Cancer|Lung Cancer|Non-Hodgkin's Lymphoma|Ovarian Cancer
Interventions: DRUG: Neulasta (pegfilgrastim)
Sponsor: Amgen